This partnership
is personal

Today’s genomic solutions for tomorrow’s cancer breakthroughs


An expanding next-generation sequencing (NGS) oncology portfolio is helping Illumina drive the revolution in cancer genomics. Our NGS and microarray technologies are among the most trusted in the world. Our sample-to-data solutions deliver high-quality, reproducible results to speed the discovery and analysis of cancer-related variants—and potentially transform the cancer care cycle.

We’re committed to advancing and individualizing the way cancer will be identified and treated. We want to partner with you in helping propel progress in personalized oncology. Together we can work toward achieving our ultimate goal: to make discoveries that will make a life-changing difference to cancer patients and their loved ones.

Cancer Genomics Research

Keep ahead of the genomics technology curve to improve the quality of your research.

Pathology & Clinical Cancer Research

Expand your sequencing capabilities—and the accuracy and potential impact of your lab.

Future of NGS in Oncology

See how NGS might help improve cancer treatment and outcomes.

Cancer Companion Diagnostics

Enhance the power and promise of your companion diagnostics capabilities.


In this talk, Swetha Anandhan from the MD Anderson Cancer Center will highlight the use of single cell RNA-sequencing to identify a unique population of macrophages in glioblastoma multiforme that persists after treatment with immune checkpoint inhibitors.

View Webinar
Interested in receiving newsletters, case studies, and information on cancer genomics? Enter your email address.